Novartis 1st-quarter financials miss expectations

27 April 2021
2020_novartis_big

Swiss pharma giant Novartis (NOVN: VX) today released first-quarter 2021 financial results, which failed to meet analysts’ expectations.

Net sales were $12.4 billion (+1%, -2% constant currency) in the first quarter driven by volume growth of 3 percentage points, price erosion of 2 percentage points and negative impact from generic competition of 3 percentage points. This compared to $12.5 billion forecast in the Refinitiv poll. Excluding prior year COVID-19 related forward purchasing, Novartis estimates first quarter net sales grew 1% (cc, +4% USD).

Core net income was $3.4 billion (-4%, -6% cc) mainly driven by the decline in core operating income, compared to the $3.5 billion average estimates of nine analysts in a poll by Refinitiv. Core EPS was $1.52 (-3%, -5% cc), declining less than core net income, benefiting from lower weighted average number of shares outstanding.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical